PEB.NZX
Pacific Edge Limited
Our view
You need to become a client or login to see Forsyth Barr’s current view.
Recent research View all research
About Pacific Edge Limited
Pacific Edge (PEB) is a cancer diagnostics company in the early stages of commercialising its first product, Cxbladder. Investors continue to require patience, with the large US market challenging to secure reimbursement. Changing established clinical processes takes time, albeit early signs remain encouraging. PEB is a speculative risk stock, reliant on converting key groups to commercial customers, with timing highly unpredictable. Its cash balance offers limited flexibility, however, the prize is large and things could change quickly.
Forsyth Barr Analyst
-
Chelsea Leadbetter, Senior Analyst, Equities
[email protected]
DDI: +64 4 495 5262
Share price performance
All stock prices and news delayed 20 minutes
08:23 July 22nd 2019 NZST
0.21 0.0%
0.21 Buy
0.21 Sell
Last --
Open --
High --
Low --
Volume -
Turnover -
Most recent trades All trades for the day
| Time | Price | Volume | Value |
|---|
Latest Pacific Edge Limited research
Today's trades
| Trade Number | Time | Price | Volume | Value |
|---|